Obesity
📧 Sign up to get email alerts when something new happens for Obesity.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-10-19FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for the phentermine and topiramate combination by Prasco Laboratories.
-
FDA approval · 2020-08-05FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for liraglutide. The approval updates the product's labeling/indicati…
-
FDA approval · 2020-08-04FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) from Nalpropion…
-
FDA approval · 2020-03-25FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Saxenda (liraglutide) from Novo Nordisk, updating the product's labeling. The approval pertains …
-
FDA approval · 2018-12-04FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
FDA approves a supplemental application for Saxenda (liraglutide) submitted by Novo Nordisk.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-06-13FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
The FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE, a fixed-dose combination of naltrexone hydrochloride and bupropio…
-
FDA approval · 2018-03-23FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for phentermine and topiramate from Prasco Laboratories, updating the label for obesity weight-manag…
-
FDA approval · 2017-08-25FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for liraglutide submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (KVK-Tech, Inc.)
The FDA approved a supplemental application for a generic phentermine hydrochloride product from KVK-Tech, Inc.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Precision Dose Inc.)
FDA approved a supplemental application for phentermine hydrochloride from Precision Dose Inc., confirming the approval of the generic drug'…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Aurolife Pharma, LLC)
The FDA granted approval for a supplemental application for Phentermine hydrochloride manufactured by Aurolife Pharma, LLC.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
FDA approved a supplemental application for phentermine hydrochloride from Sunrise Pharmaceutical, Inc., under an existing ANDA.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
The FDA approved a supplemental application for phentermine hydrochloride from Sunrise Pharmaceutical, Inc.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (POLYGEN PHARMACEUTICALS INC.)
FDA approved a supplemental application for phentermine hydrochloride from PolyGen Pharmaceuticals Inc., indicating an updated approval stat…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE — Supplemental Application (Aurolife Pharma, LLC)
FDA approved a supplemental application for phentermine hydrochloride (phentermine) from Aurolife Pharma, LLC, under ANDA204318, authorizing…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (KVK-TECH, Inc.)
The FDA approved a supplemental application for phentermine hydrochloride submitted by KVK-Tech, Inc. This action updates the approval statu…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (TAGI Pharma, Inc.)
FDA approved TAGI Pharma, Inc.'s supplemental application for phentermine hydrochloride, a weight-management drug.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for phentermine hydrochloride from Sun Pharmaceutical Industries, Inc. to update the product labelin…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
FDA approved the supplemental application for phentermine hydrochloride by Epic Pharma, LLC, granting approval of a generic version of the o…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for phentermine hydrochloride submitted by Solco Healthcare U.S., LLC.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (KVK-Tech, Inc.)
FDA approved a supplemental application for phentermine hydrochloride submitted by KVK-Tech, Inc., indicating a label/formulation-related up…
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
FDA approved Sunrise Pharmaceutical's supplemental application for phentermine hydrochloride, a generic weight-management medication.
-
FDA approval · 2017-05-31FDA Approved: PHENTERMINE HYDROCHLORIDE — Supplemental Application (Elite Laboratories, Inc.)
The FDA approved a supplemental application for phentermine hydrochloride submitted by Elite Laboratories, Inc. This action updates the appr…
-
FDA approval · 2017-05-22FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
FDA approves a supplemental application for SAXENDA (liraglutide) from Novo Nordisk.
-
FDA approval · 2017-05-15FDA Approved: ALLI — Supplemental Application (Haleon US Holdings LLC)
FDA approves a supplemental application for ALLI (orlistat) submitted by Haleon US Holdings LLC.